Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3427 dose-ranging study in heart failure with pulmonary hypertension due to left heart disease
NL-OMON60462Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD3427 in heart failure (HF) and pulmonary hypertension due to left heart disease (PH-LHD), sponsored by AstraZeneca. Primary endpoint: Change in pulmonary vascular resistance. Started Sep 2023; status: completed.
02
Drugs
AZD3427
03
Conditions
heart failure (HF)pulmonary hypertension due to left heart disease (PH-LHD)
Beyond the preview
Go deeper on NL-OMON60462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60462.